[{"id":"b30a8bca-2be6-49b4-90f3-03ff7a00b1ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT04586270","created_at":"2021-01-18T21:52:48.356Z","updated_at":"2024-07-02T16:34:37.959Z","phase":"Phase 1","brief_title":"A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer","source_id_and_acronym":"NCT04586270","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" HER-2 • KRAS • PTEN • NF1","pipe":" | ","alterations":" KRAS mutation • HR positive • KRAS G12C • HER-2 negative • KRAS G12D • NF1 mutation • KRAS G12 • HR positive + HER-2 negative","tags":["HER-2 • KRAS • PTEN • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • HR positive • KRAS G12C • HER-2 negative • KRAS G12D • NF1 mutation • KRAS G12 • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAS0612"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-06-05"}]